Sy Mukherjee, Fortune

Sy Mukherjee


New York, NY, United States

Contact Sy

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Fortune

Recent articles by Sy:

CVS CEO Merlo on the Company's Future One Year After Aetna Acquisition

CVS chief Larry Merlo discussed what's happened in the year since acquiring insurer Aetna—and what comes next. → Read More

The Broader Implications of Biogen’s Divisive Alzheimer’s Drug

Analyst reactions to Biogen's new Alzheimer's drug data were mixed. But the implications for treating the disease are far broader. → Read More

5 Health Leaders on the Trust Deficit in U.S. Medicine

In a wide-ranging dinner conversation, health leaders from Toby Cosgrove to Arianna Huffington discussed why patients don't trust U.S. medicine and data use—and how to fix it. → Read More

The Gene Therapy Spree Rolls on With $3 Billion Astellas Deal

Japan's Astellas is snatching up Audentes Therapeutics in a $3 billion gene therapy deal—part of a growing trend among pharma companies. → Read More

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping

Dr. Stephen Hahn was approved by a Senate panel to lead the FDA on Tuesday. But he faced scrutiny on the future of vaping and e-cig regulation. → Read More

Biogen Stock Tumbles on Brutal Takedown of Its Alzheimer's Drug Bet

Biogen revived an Alzheimer's drug that had been left for dead. But at least one analyst is pouring cold water on the aducanumab bet, and Biogen stock fell Monday. → Read More

Parents of Children With Diabetes Are Furious Following the Blackout of a Major Blood Sugar Monitoring Software

Dexcom's popular glucose monitoring software alerts went dark over Thanksgiving weekend, enraging the parents of children with diabetes. → Read More

Is Thanksgiving Good, or Bad, for Your Mental Health?

Holidays like Thanksgiving can be stressful for some. But social bonds are also helpful for mental health. → Read More

American Life Expectancy Is Still Dropping. But Why?

A spike in drug overdoses, suicides, and other factors continues to dog life expectancy in the U.S., according to a new study. → Read More

Novartis' $9.7 Billion Deal Sets off Heart Drug Wars

Novartis is buying cholesterol drug maker The Medicines Company at a sharp premium—and it's setting off speculation about future heart drug deals. → Read More

Which Medicines Have Transformed Drug Development in the Past Decade?

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here. Happy Friday, readers! I have a selfish request of all of you this evening. If you have any thoughts about which drugs, medicines, therapies, procedures, etc have served […] → Read More

Exclusive: This Doctor Wants to Use Salesforce Blockchain to Cut Cancer Drug Development Costs in Half

Renowned UCSF oncologist Laura Esserman wants to use Salesforce Blockchain to slash the cost of breast cancer drug development. → Read More

OxyContin’s Maker Is Still Flourishing In China

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here. Good afternoon, readers. The opioid addiction crisis that’s killed or otherwise sickened millions of Americans has galvanized significant backlash. Alleged perpetrators range from drug developers to drug distributors […] → Read More

A Small Study Raises Big Hopes That Gene-Editing Can Treat Blood Diseases

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here. Good afternoon, readers. Sometimes, a small study can raise big expectations—especially in the nascent industry of gene-editing to treat serious diseases. Such is the case for CTX001, a […] → Read More

2 CEOs on the Future of Digital Health

Happy Monday, readers! I hope you enjoyed your weekend. Fortune‘s 2019 Global Forum began on Monday in Paris. I encourage readers to catch up on the panels, one-on-one interviews, and conversations with some of the most consequential figures in business and government. On the health care front, here’s what I found intriguing: A back-and-forth between […] → Read More

Why Virtual Brain Simulations Are the Future of Health Care

GE Healthcare's and Dassault Systèmes's CEOs explain the future of digital health at Fortune's 2019 Global Forum in Paris. → Read More

The Source of Facebook's Anti-Vaccine Ads

A new study traces the majority of vaccine misinformation on Facebook to two groups. → Read More

China Biotech BeiGene Wins FDA Approval for Rare Blood Cancer Drug

The FDA has approved China-based biotech BeiGene's blood cancer drug. The victory could boost Amgen—and China's drug industry at large. → Read More

The Tiny Problem Sickening Millions of Americans: Superbugs

A new CDC report finds that nearly 3 million Americans are infected by drug-resistant superbugs every year. And more than 35,000 die. → Read More

Trump to Meet With Vaping Industry Ahead of Potential Bans

Happy Tuesday, readers. The Trump administration has been cracking down on vaping in the past year—or at least proposing some pretty serious restrictions on e-cigarette use and marketing. Those efforts include a proposed ban on flavored e-cig pods—part of a broader blowback against vaping given the recent public health horrors linked with some vaping products […] → Read More